A+ Science AB

Merck Life Science A/S

A healthy society requires more than a new pill

Sarah Lidé on how medicines are essential – but a sustainable approach to healthy societies also depends on prevention and behavioural change

A food-based strategy to stop gut infections early

Most gastrointestinal infections are treated only after symptoms have already developed. Researcher Andreas Hougaard Laustsen-Kiel aims to reduce risk earlier b...

Björn Arvidsson: ”As uncertainty grows, clarity becomes a strength”

Sweden has all the prerequisites to be a strong life science nation. But in a time of geopolitical tension, shorter value chains and growing demands for resilie...

Thermo Fisher Expands in Sweden – “We Are Sending a Clear Message”

The American life science giant Thermo Fisher Scientific has inaugurated a new distribution center in Uppsala. “By investing in increasing our capacity as well ...

Webinar: Enhancing Assay Sensitivity with Signal Amplification in a Microfluidic Assay

19 MARS 2026: Lyssna på vår gästtalare, Dr. Linda Klauss från Gyros Protein Technologies, när hon håller i ett exklusivt webbinarium där vi visar hur kombinatio...

New global standard for clinical evaluation is on the horizon: ISO/DIS 18969

A new global standard for clinical evaluation is on the horizon: ISO/DIS 18969. The core message is straightforward: clinical evaluations should be seen as a pr...

QAdvis is now Aurevia

Two years ago, QAdvis became part of something bigger. At first, the change was mostly visible on paper — a new owner and later a new name: Aurevia. But this wa...

GSK eyes blockbuster potential – plans five new trials

GSK sees blockbuster potential in its experimental drug candidate Mo-rez. Early trial results suggest the treatment may shrink tumours in patients with advanced...

“Ozempic babies” – myth or reality?

Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.

ZEISS and EDGE leverage AI to transform bioimaging in the biopharma industry

Transforming complex bioimaging data to workflows offering actionable insights for decision-making to speed up drug discovery.

Dive Into Current Metrology Trends

ZEISS INNOVATION TALKS - new video podcast series.

Breakfast meeting in Norway: Essential Insights for Life Science Leaders on AI and Patient Journeys

We are pleased to invite you to an inspiring session with Niels Buch Leander, Chief Digital Officer at PharmaRelations.

Medicon Village breakfast seminar: ISO 10993-1 in practice

Don't miss our breakfast seminar at Medicon Village on May 28th: ISO 10993-1 in practice - connecting biological evaluation to your technical documentation.

Upcoming training: Introduction to ISO 15189:2022

Do you work with quality management in a medical laboratory? Don’t miss our ISO 15189:2022 online training course on May 12-13th — designed to help you understa...

Quality management system according to EN ISO 13485:2016 – in practice

Do you work with medical devices? Understanding and implementing a robust Quality Management System (QMS) is key to regulatory success—and often a prerequisite for CE-marking.

GLP-1 profile leaves Novo Nordisk after 36 years

Lotte Bjerre Knudsen, one of the key figures behind Novo Nordisk’s success in obesity medicines, is leaving the company after more than three decades.

First injectable cancer medicine for home use receives green light

Johnson & Johnson has announced that its blockbuster cancer medicine Darzalex (daratumumab) is set to become the first injectable cancer treatment in Europe sui...

Swedish industrial group Alfa Laval establishes pharmaceutical division

Alfa Laval is creating a new division focused on tailored solutions for the pharmaceutical industry.

Custom regulatory and clinical strategy workshops

A strong regulatory and clinical strategy early on can save months of rework later.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Drug approved for condition causing extreme hunger

The U.S. Food and Drug Administration (FDA) has for the first time approved a drug for acquired hypothalamic obesity, a condition marked by rapid weight gain dr...

Disappointment for Diamyd in Phase III – the share price plunges

Diamyd Medical’s share was sharply down on Monday following negative Phase III results. “This outcome is highly unexpected,” said the company’s CEO, Ulf Hannelius.